Although unparalleled clinical efficacy has been achieved using chimeric antigen receptor (CAR) redirected T cells to treat liquid malignancies, such as B-cell hematologic tumors, their use against solid tumors has faced many challenges. Now, a favorable safety profile of an experimental T-cell therapy for liver cancer has been announced at the 2018 CAR-TCR Summit in Boston, Massachusetts.
The findings, from an ongoing proof-of-concept first-in-human study, which is being conducted at the First Affiliated Hospital of Xi’An Jiaotong University in China, showed a positive safety profile of ET140202 T-cell therapy in six patients with no observed cytokine release syndrome (CRS) or drug-related neurotoxicity. In addition, one patient in the i.v. arm of the study had a complete response.
Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company that developed the novel T-cell therapy, expects to begin multi-center phase 1 clinical trials of ET140202 in 2019.
ET140202 utilizes Eureka’s proprietary ARTEMIS™ T-cell receptor platform engineered with a proprietary human T cell receptor mimic (TCRm) antibody to target an AFP-peptide/HLA-A2 complex on HCC cancer cells.
Using its proprietary E-ALPHA® antibody discovery platform, Eureka discovered and developed a TCRm antibody to selectively bind upon fragments or peptides of the AFP protein that are broken down within the cancer cell proteasome and displayed on the cell surface by the major histocompatibility complex (MHC). Once engaged onto this complex, the ET140202 engineered T-cell is designed to be activated to kill the cancer cell.
“We are encouraged by the safety profile and the potential efficacy of ET140202 for AFP-positive liver cancer. Combining T-cell therapy with a TCR-mimic antibody to target intracellular antigens is a novel approach and can potentially represent a powerful way to treat solid tumors, and in particular, liver cancer, an area of significant unmet medical need. The initial results represent an important milestone in T-cell therapy against solid tumors, and we intend to continue to study and rapidly advance ET140202 into Phase 1 clinical trials in the United States,”
said Cheng Liu, Ph.D., President and Chief Executive Officer of Eureka Therapeutics.
As of the data cutoff date of July 2018, six patients who had previously failed multiple lines of therapy had been treated in one of three treatment arms of ET140202: intravenous (i.v.), intra-hepatic artery (i.a.) infusion or intratumoral (i.t.) injection. All patients enrolled in this study were AFP-expressing HCC patients carrying at least one HLA-A2 allele. All six patients had pre-existing cirrhosis.
In vivo T-cell expansion, which indicates T-cell activation, was observed in all six patients. Reduction of serum AFP was observed in four out of the six patients.
A complete response was observed in one patient at the five-month assessment, with tumor regression observed in both the primary liver tumors and distal lung metastases after multiple treatment doses.
In addition, the serum AFP of this patient returned to normal levels at the five-month assessment. The complete response was maintained at the seven-month assessment.
Among other patients with one to three months of follow-up, two patients showed partial tumor regression, two patients showed stable disease and one patient showed progressive disease. Of the six patients, three died due to non-drug-related complications of liver disease. Two of these three patients showed a partial response at the one-month follow-up assessment.
Across all evaluable patients, ET140202 was generally well-tolerated. All drug-related adverse events reported by investigators were limited to Grades 1 or 2, with the most common being fever and fatigue.
Liver cancer is the second most common cause of cancer-related deaths, with roughly 600,000 patient deaths every year worldwide, with incidence rates on the rise and limited treatment options. Between 2000 and 2016, mortality rates in liver cancer have increased 43% in the United States.
Hepatocellular carcinoma is the predominant type of liver cancer with approximately 31,500 cases per year occurring in the United States. Alpha-fetoprotein (AFP) is overexpressed, specifically in liver cancer, making it an ideal target for T-cell immunotherapy.
However, AFP is intracellularly expressed and secreted, and therefore, not targetable by conventional antibody-based therapies.
“Hepatocellular carcinoma is a cancer where we have had great difficulties finding effective treatments. The study shows early but important data in the possibility of targeting solid tumors using T-cell therapy. ET140202 has demonstrated a large therapeutic window with the potential of repeat dosing, combination therapy, as well as a higher dosing level than we have seen with other T-cell programs. I look forward to seeing future data on this study,”
said liver cancer surgeon and researcher Yuman Fong, M.D..
Sarwish Rafiq, Oladapo O Yeku, Hollie J Jackson, Terence J Purdon, Dayenne G van Leeuwen, Dylan J Drakes, Mei Song, Matthew M Miele, Zhuoning Li, Pei Wang, Su Yan, Jingyi Xiang, Xiaojing Ma, Venkatraman E Seshan, Ronald C Hendrickson, Cheng Liu & Renier J Brentjens Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo Nature Biotechnology 13 August 2018